These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36874018)

  • 1. The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China.
    Wen X; Wang Y; Chen X; Liu Y; Mao Z
    Front Pharmacol; 2023; 14():1088723. PubMed ID: 36874018
    [No Abstract]   [Full Text] [Related]  

  • 2. The Impact of a National Stewardship Policy on the Usage Patterns of Key Monitoring Drugs in a Tertiary Teaching Hospital: An Interrupted Time Series Analysis.
    Li H; McIver DJ; Ji W; Du J; Zhao H; Jia X; Zhai Y; Xue X
    Front Pharmacol; 2022; 13():847353. PubMed ID: 35250599
    [No Abstract]   [Full Text] [Related]  

  • 3. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis.
    Wen X; Yin S; Cui L; Mao L; Lin Z; Yaermaimaiti Z; Geng X; Li Y; Yang Y; Cui D; Mao Z
    Front Public Health; 2021; 9():718013. PubMed ID: 34760861
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
    Lan T; Guan L; Pang X; Li X; Yu Q
    J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Prescribing Monitoring Policy on Drug Use and Expenditures in China: A Multi-center Interrupted Time Series Study.
    Nie X; Wang R; Liang G; Zhang X; Tang N; Cai Y; Han C; Zhao Y; Jia T; Zhang F; Han S; Guan X; Shi L; Lu CY
    Int J Health Policy Manag; 2023; 12():7343. PubMed ID: 37579366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
    Yang Y; Chen L; Ke X; Mao Z; Zheng B
    BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
    Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
    Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
    Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
    Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
    Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
    Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of '4+7' volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China.
    Wang J; Yang Y; Xu L; Shen Y; Wen X; Mao L; Wang Q; Cui D; Mao Z
    BMJ Open; 2022 Mar; 12(3):e054346. PubMed ID: 35288385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
    Wang N; Yang Y; Xu L; Mao Z; Cui D
    BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study.
    Gao X; Yu M; Sun Y; Zhang T; Li X; Zhang L; Wang C
    Risk Manag Healthc Policy; 2024; 17():2201-2208. PubMed ID: 39309121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis.
    Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z
    BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
    Wang J; Li P; Wen J
    BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China.
    Wen X; Xu L; Chen X; Wu R; Luo J; Wan Y; Mao Z
    Front Pharmacol; 2023; 14():984794. PubMed ID: 37731741
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of the Expert Consensus on Carbapenem Consumption Trends and Patterns in Public Healthcare Institutes: An Interrupted Time Series Analysis, 2017-2020.
    Ye D; Yang C; Ji W; Zheng J; Zhang J; Xue R; Gu J; Chen M; Yan K; Liu Y
    Front Pharmacol; 2021; 12():739960. PubMed ID: 35095482
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016-2018: an interrupted time series study in Shaanxi.
    Yan K; Yang C; Zhang H; Ye D; Liu S; Chang J; Jiang M; Zhao M; Fang Y
    BMJ Open; 2020 Nov; 10(11):e037034. PubMed ID: 33243788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
    Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
    J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.